FDA's Media Frenzy
This article was originally published in RPM Report
The Food & Drug Administration is trying to reverse its negative image tide by adopting a more proactive relationship with the news media. Over one five-week period alone, FDA held almost a dozen media teleconference calls on drug- or biologic-related issues. The extra attention is either good or bad news for manufacturers, depending on the subject of the media briefing.
You may also be interested in...
GlaxoSmithKline's diabetes drug Avandia survived a perilous FDA advisory committee review. The real question is whether the industry can survive the damage to FDA's credibility.
An FDA advisory committee call for immediate action on attention deficit/hyperactivity disorder drug safety leaves the agency scrambling to defend itself.
FDA plans to "lock up" reporters before major drug safety announcements in order to brief them more thoroughly and give them access to agency experts. FDA is working on a policy paper related to its external relations efforts.